Norcantharidin ameliorates proteinuria, associated tubulointerstitial inflammation and fibrosis in protein overload nephropathy

American Journal of Nephrology

Volumn 28, Issue 3, 2008, Pages 465-477

  Liu, Fu You ^a   Li, Ying ^a   Peng, You Ming ^a   Ye, Kun ^a   Li, Jun ^a   Liu, Ying Hong ^a   Duan, Shao Bin ^a   Ling, Guang Hui ^a   Xu, Xiang Qing ^a   Zhou, Le Tian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Connective tissue growth factor; Fibrosis; Interstitial inflammation; Norcantharidin; Nuclear factor B; Proteinuria

Indexed keywords

BOVINE SERUM ALBUMIN; CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NORCANTHARIDIN; SYNAPTOTAGMIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN OVERLOAD NEPHROPATHY; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; FIBROSIS; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; NEPHRITIS, INTERSTITIAL; NF-KAPPA B; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 41849085477     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112850     Document Type: Article

References (36)

1. Liu FY, Li Y, Peng YM, Yang L, Duan SB, Li J, Chen X, Xia YC, Guo N, Xu XQ: Relationship between clinical predictors and tubulointerstitial damage in adult-onset primary nephrotic syndrome. Arch Med Res 2006;37:981-986.
2. Hirschberg R, Wang S: Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 2005;14:43-52.
3. Palmer BF: Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007;27:287-293.
4. McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, Baldwin ML: Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 2000;10:1687-1690.
5. Sakoff JA, Ackland SP, Baldwin ML, Keane MA, McCluskey A: Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Invest New Drugs 2002;20:1-11.
6. Wei CM, Wang BJ, Ma Y, Sun ZP, Li XL, Guo RC: Pharmacokinetics and biodistribution of 3 H-norcantharidin in mice. Yao Xue Xue Bao 2007;42:516-519.
7. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF, Hsu SL: Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002;100:158-165.
8. Liu XH, Blazsek I, Comisso M, Legras S, Marion S, Quittet P, Anjo A, Wang GS, Misset JL: Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 1995;31A:953-963.
9. Baba Y, Hirukawa N, Tanohira N, Sodeoka M: Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin). J Am Chem Soc 2003;125:9740-9749.
10. Eddy AA, Kim H, López-Guisa J, Oda T, Soloway PD: Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int 2000;58:618-628.
11. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16:2063-2072.
12. Nakayama H, Ikebe T, Beppu M, Shirasuna K: High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001;92:3037-3044.
13. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217-3232.
14. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD: Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006;48:8-20.
15. Doggrell SA: ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Expert Opin Pharmacother 2003;4:1185-1188.
16. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124.
17. Taal MW, Brenner BM: Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens 2002;11:377-381.
18. Ha IS, Um EY, Jung HR, Park HW, Cheong HI, Choi Y: Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 2002;39:1001-1010.
19. Peng A, Gu Y, Lin SY: Herbal treatment for renal diseases. Ann Acad Med Singapore 2005;34:44-51.
20. Williams LA, Moller W, Merisor E, Kraus W, Rosner H: In vitro anti-proliferation/cytotoxic activity of cantharidin (Spanish fly) and related derivatives. West Indian Med J 2003;52:10-13.
21. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G, Han X: Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 2001;44:2065-2068.
22. McCluskey A, Ackland SP, Bowyer MC, Baldwin ML, Garner J, Walkom CC, Sakoff JA: Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem 2003;31:68-79.
23. Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO: Norcantharidin inhibits growth of human Hep G2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997;117:93-98.
24. Yi SN, Wass J, Vincent P, Iland H: Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991;15:883-886.
25. Weening JJ, Van Guldener C, Daha MR, Klar N, van der Wal A, Prins FA: The pathophysiology of protein-overload proteinuria. Am J Pathol 1987;129:64-73.
26. Schieppati A, Remuzzi G: Proteinuria and its consequences in renal disease. Acta Paediatr Suppl 2003;92:9-13.
27. 2 through a PKC dependent pathway. J Am Soc Nephrol 2002;13:1179-1189.
28. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int 1998;53:1608-1615.
29. Wang Y, Rangan GK, Tay Y-C, Wang Y, Harris DC: Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor κB in proximal tubule cells. J Am Soc Nephrol 1999;10:1204-1213.
30. Mezzano SA, Barría M, Droguett MA, Burgos ME, Ardiles LG, Flores C, Egido J: Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001;60:1366-1377.
31. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Eqido J: Activation of NF-κB in tubular epithelial cells of rats with intense proteinuria. Role of angiotensin II and endothelin-1. Hypertension 2001;37:1171-1178.
32. Perbal B: CCN proteins: multifunctional signalling regulators. Lancet 2004;363:62-64.
33. Rupérez M, Ruiz-Ortega M, Esteban V, Lorenzo O, Mezzano S, Plaza JJ, Eqido J: Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003;163:1937-1947.
34. Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, Sugaya T, Kopp JB, Suzuki H: Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005;16:133-143.
35. Miller JL, Ericson SG: Cyclosporin A and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo. Immunopharmacol Immunotoxicol 2007;29:105-118.
36. Yan MS, Xiue S, Wei LX, Piao XH: The preliminary observation on immuno-suppressive effect of norcantharidin in mice. Immunopharmacol Immunotoxicol 1993;15:79-85.